HIGHLIGHTS
- who: Cancer immunotherapy and collaborators from the Universitu00e9 Paris-Saclay, Villejuif, France have published the article: Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises, in the Journal: (JOURNAL)
- what: The present review discusses tumor-associated antigens (TAAs) and neoantigens and their use as targets in peptide- and RNA-based therapeutic vaccines.
- future: These mutant neoantigens have opened up new perspectives in active immunotherapy to a wide range of cancer types without the need for isolating tumor-reactive CTL clones and establishing autologous cancer cell lines . The design of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.